← Back to Search

Brachytherapy

Shorter-lasting vs Standard Radiation for Prostate Cancer

Phase 3
Waitlist Available
Led By Kent E Wallner, MD
Research Sponsored by VA Puget Sound Health Care System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Gleason score 5 or 6
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing whether a shorter-lasting radiation treatment will be more effective at treating prostate cancer. 660 patients will be randomly assigned to either the shorter-lasting treatment or the standard treatment.

Who is the study for?
This trial is for men with medium-risk prostate cancer, specifically those who have a Gleason score of 5 or 6 and PSA levels between 4-10 ng/ml. It's not suitable for individuals outside these criteria.Check my eligibility
What is being tested?
The study is testing the effectiveness of two radioactive seeds in treating prostate cancer: Iodine-125 (I-125) and Palladium-103 (Pd-103). The hypothesis suggests that Pd-103's shorter half-life could lead to faster tumor eradication compared to I-125.See study design
What are the potential side effects?
Possible side effects from the seed implants may include discomfort at the implant site, urinary issues such as frequency or urgency, erectile dysfunction, bowel changes, and temporary pain or swelling.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate cancer has a low Gleason score.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PSA-based cancer eradication

Find a Location

Who is running the clinical trial?

VA Puget Sound Health Care SystemLead Sponsor
63 Previous Clinical Trials
227,073 Total Patients Enrolled
3 Trials studying Prostate Cancer
1,215 Patients Enrolled for Prostate Cancer
Dr. Gregory MerrickUNKNOWN
Theragenics CorporationIndustry Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

I-125 (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00486499 — Phase 3
Prostate Cancer Research Study Groups:
Prostate Cancer Clinical Trial 2023: I-125 Highlights & Side Effects. Trial Name: NCT00486499 — Phase 3
I-125 (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00486499 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I fit the criteria to partake in this research?

"Prostate cancer patients that are between 40 and 90 years old may be eligible for this 660-person clinical trial."

Answered by AI

Are there any risks associated with this treatment?

"This intervention has undergone Phase 3 clinical trials, which is the last stage before FDA approval. This means that there is data supporting both its efficacy and safety, so it received a score of 3."

Answered by AI

Are elderly patients above the age of 70 able to participate in this particular experiment?

"The age requirements to participate in this trial are between 40-90 years old."

Answered by AI

Are there any unfilled roles in this research project?

"Unfortunately, this particular clinical trial is no longer recruiting patients. This is according to the most recent update on clinicaltrials.gov which was from June 12th, 2007. Although, there are 1,364 other studies that are currently enrolling participants."

Answered by AI
~30 spots leftby Mar 2025